Fig. 3

MRI examination of patient A during the combined treatment. A–C Before administering the combination therapy. D–F After 9 weeks of apatinib in combination with sintilimab therapy. G–I After 7 months of lenvatinib in combination with sintilimab therapy. The blue arrows indicate the position of lesions at the early arterial enhancement stage. The yellow arrows indicate the position of lesions at the portal vein stage. The red arrows indicate the position of PVTT